{"title":"五味子甲素联合索拉非尼治疗晚期肝癌耐药的疗效研究","authors":"麒洋 程","doi":"10.12677/wjcr.2023.133018","DOIUrl":null,"url":null,"abstract":"Sorafenib (So) is a new multi-targeted first-line oral drug for the treatment of advanced hepatocel-*","PeriodicalId":286101,"journal":{"name":"World Journal of Cancer Research","volume":"120 3 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Study on the Efficacy of Combination Drugs of Schisantherin A and Sorafenib in the Treatment of Drug Resistance in Advanced Hepatocellular Carcinoma\",\"authors\":\"麒洋 程\",\"doi\":\"10.12677/wjcr.2023.133018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sorafenib (So) is a new multi-targeted first-line oral drug for the treatment of advanced hepatocel-*\",\"PeriodicalId\":286101,\"journal\":{\"name\":\"World Journal of Cancer Research\",\"volume\":\"120 3 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Cancer Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12677/wjcr.2023.133018\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Cancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12677/wjcr.2023.133018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
